Clinical Trials Logo

Clinical Trial Summary

This is a Phase 2 clinical trial evaluating the efficacy and safety of sintilimab in subjects with CUP. Up to 45 subjects with CUP will be enrolled. Subjects will be treated with sintilimab at 200 mg via intravenous (IV) administration on Cycle 1 Day 1. The treatment will repeat every 3 weeks until progressive disease (PD), intolerable toxicity, initiation of new anti-tumor therapy, withdrawal of consent, lost to follow-up, death, completion of therapy, or any other investigator-determined reasons for treatment discontinuation (whichever occurs first). Treatment will continue for a maximum period of 24 months (starting from the first dose). During the trial, tumor imaging evaluation will be initially performed once every 9 weeks (± 7 days) and will be based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. After the completion or discontinuation of the study treatment, safety follow-up and survival follow-up will be performed. Considering the rareness of the disease, the patient accrual rate is expected to be approximately 2 patients per month. The total study duration is expected to be between 24-27 months with 6-month follow up.

Clinical Trial Description

Primary Objectives: - To evaluate the safety and efficacy of sintilimab in subjects with CUP Secondary Objectives: - To evaluate the overall objective response rate (ORR) (investigator assessed), disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), overall survival (OS) and Quality of Life (QOL) on sintilimab in subjects with CUP Exploratory Objectives: - To evaluate the correlation between biomarkers in tumor tissue and efficacy, including but not restricted to PD-L1 expression level, transcriptome sequencing, single-cell sequencing, and multicolor immunohistochemistry (IHC) analyses; - To evaluate the correlation between biomarkers in peripheral blood and drug efficacy, including but not restricted to soluble PD-L1, circulating tumor DNA (ctDNA), and cytokine analyses. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05024968
Study type Interventional
Source M.D. Anderson Cancer Center
Contact Alma DeLaGarza
Phone 713-792-5111
Email [email protected]
Status Recruiting
Phase Phase 2
Start date August 26, 2021
Completion date January 2, 2023

See also
  Status Clinical Trial Phase
Completed NCT03278600 - Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary Phase 3
Recruiting NCT04504604 - TCF-001 TRACK (Target Rare Cancer Knowledge) Study N/A
Active, not recruiting NCT03053466 - APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors Phase 1
Recruiting NCT04750109 - Carcinoma of Unknown Primary (CUP): A Comparison Across Tissue and Liquid Biomarkers
Recruiting NCT04952103 - Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China
Recruiting NCT03498521 - A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Phase 2
Active, not recruiting NCT01845337 - Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine Phase 2
Recruiting NCT03752333 - Trial of Pembrolizumab in Cancer of Unknown Primary Phase 2
Recruiting NCT04131621 - Nivolumab/Ipilimumab in Second Line CUP-syndrome Phase 2